Hypogonadism in young men treated for cancer.
(2015) In Hormones: International Journal of Endocrinology and Metabolism 14(4). p.392-398- Abstract
- An ever-increasing proportion of young males treated for cancer are cured. Therefore, one of the major challenges of modern Clinical Oncology is to ensure good quality of life. Cancer disease per se as well as cancer treatment may have a negative impact on androgen production, thereby leading to subclinical or clinically overt hypogonadism. Since the symptoms of androgen deficiency are rather unspecific, it is important that reproductive hormone levels be checked in young men who have been treated for cancer. As androgen deficiency in men is associated with increased long-term risk of osteoporosis as well as cardiovascular and metabolic disease, those cancer survivors who present with signs of insufficient androgen production should be... (More)
- An ever-increasing proportion of young males treated for cancer are cured. Therefore, one of the major challenges of modern Clinical Oncology is to ensure good quality of life. Cancer disease per se as well as cancer treatment may have a negative impact on androgen production, thereby leading to subclinical or clinically overt hypogonadism. Since the symptoms of androgen deficiency are rather unspecific, it is important that reproductive hormone levels be checked in young men who have been treated for cancer. As androgen deficiency in men is associated with increased long-term risk of osteoporosis as well as cardiovascular and metabolic disease, those cancer survivors who present with signs of insufficient androgen production should be followed and preventive as well as therapeutic measures, including androgen replacement therapy, should be applied according to the current guidelines. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8826072
- author
- Giwercman, Aleksander LU and Giwercman, Yvonne LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Hormones: International Journal of Endocrinology and Metabolism
- volume
- 14
- issue
- 4
- pages
- 392 - 398
- publisher
- Hellenic Endocrine Society
- external identifiers
-
- pmid:26859600
- scopus:84957625702
- pmid:26859600
- ISSN
- 1109-3099
- DOI
- 10.14310/horm.2002.1650
- language
- English
- LU publication?
- yes
- id
- c6907213-30b3-4479-b116-a0431c32de57 (old id 8826072)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26859600?dopt=Abstract
- date added to LUP
- 2016-04-04 09:39:14
- date last changed
- 2022-01-29 18:54:12
@article{c6907213-30b3-4479-b116-a0431c32de57,
abstract = {{An ever-increasing proportion of young males treated for cancer are cured. Therefore, one of the major challenges of modern Clinical Oncology is to ensure good quality of life. Cancer disease per se as well as cancer treatment may have a negative impact on androgen production, thereby leading to subclinical or clinically overt hypogonadism. Since the symptoms of androgen deficiency are rather unspecific, it is important that reproductive hormone levels be checked in young men who have been treated for cancer. As androgen deficiency in men is associated with increased long-term risk of osteoporosis as well as cardiovascular and metabolic disease, those cancer survivors who present with signs of insufficient androgen production should be followed and preventive as well as therapeutic measures, including androgen replacement therapy, should be applied according to the current guidelines.}},
author = {{Giwercman, Aleksander and Giwercman, Yvonne}},
issn = {{1109-3099}},
language = {{eng}},
number = {{4}},
pages = {{392--398}},
publisher = {{Hellenic Endocrine Society}},
series = {{Hormones: International Journal of Endocrinology and Metabolism}},
title = {{Hypogonadism in young men treated for cancer.}},
url = {{http://dx.doi.org/10.14310/horm.2002.1650}},
doi = {{10.14310/horm.2002.1650}},
volume = {{14}},
year = {{2015}},
}